Publication

Article

Oncology & Biotech News

March 2011
Volume5
Issue 3

Palliative care shows surprising benefit

Author(s):

New research has shown that adding prompt palliative supportive care to standard treatment may not only improve mood and quality of life in cancer patients, but it may even extend survival.

Palliative Care Shows Surprising Benefits

New research published August 19, 2010, in the New England Journal of Medicine has shown that adding prompt palliative supportive care to standard treatment may not only improve mood and quality of life in cancer patients, but it may even extend survival. The study, which examined 151 metastatic non-small cell lung cancer patients, showed that those assigned to additional palliative care had a median survival of 11.6 months, compared to 8.9 months for those who received standard treatment alone. Palliative care helps the patient cope with symptom management, psychological and social effects and also serves as a spiritual aid. This type of comprehensive care helps the patients and their families handle the trauma of the illness, as well as helping them understand treatment options and cope with effects of their disease.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.